SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel ($INTC) is trending after a strong earnings report, beating expectations and forecasting continued growth. The community is discussing the potential for a short squeeze, the impact of government investments, and new partnerships. Many express confidence in the company's turnaround and future prospects in the semiconductor industry.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a recent pullback, prompting debate among investors about whether it represents a buying opportunity or a sign of deeper issues. Community discussions revolve around the stock's support levels, potential for a rebound, and the influence of broader market trends. Some investors remain confident in the company's long-term prospects within the AI and data center sectors, citing significant contracts and growth potential.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending amid speculation and a now-denied report about potential US government investment in quantum computing companies, fueling high trading volume. Community chatter focuses on whether this is a buying opportunity or a pump and dump scheme, while some highlight D-Wave's existing technology and government connections. The stock's volatility reflects broader interest and skepticism surrounding the quantum computing sector.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont (NEM) is trending as investors digest recent Q3 earnings, which beat expectations despite a drop in gold prices impacting the stock. Community discussions revolve around the CEO's performance on the earnings call and the potential for manipulation by HFs. Despite mixed sentiment, many see long-term value, citing strong earnings and revenue beats.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor (DECK) is trending as investors assess its future following recent earnings and guidance. Community discussions revolve around concerns about slowing growth and the potential impact of tariffs, despite a solid earnings report. Some see the dip as a buying opportunity, citing the company's strong brands and potential for stock buybacks, while others express caution due to market uncertainty and broader economic factors.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending following the deployment of its veriScan biometric identity platform at Chicago O'Hare International Airport, which has led to community excitement around potential TSA contracts. The company's AI-enabled biometrics are reportedly reducing passenger processing times, and some investors believe that similar deployments across other airports could drive substantial growth. Short interest remains high, and the community is closely watching for news of additional contracts or partnerships.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

B All In (BALLIN) is trending, with community members highlighting its strong momentum and potential for significant gains. The coin's association with Phantom Wallet and bullish chart patterns are key discussion points. Many users are expressing confidence and encouraging others to buy and hold.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

ALK is trending as investors await earnings, with some expressing concern over a potential delay in the release. Community members are analyzing option flows and debating whether bearish analysis will hold, or if the stock is poised for a pop. The airline sector's performance, including competitors like AAL, is also influencing sentiment.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest strong Q3 sales figures, particularly a surge in EV sales, alongside news of potential tariff relief. Community members are weighing the impact of these factors against concerns about aluminum supply disruptions and lowered 2025 guidance, impacting the stock's near-term trajectory. Discussion also centers on Ford's strategy in the evolving EV landscape and its competitive position against other automakers.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its fair launch and decentralized nature on the Bitcoin blockchain. Community members highlight its resilience during market corrections and tout the growing adoption by major players, like C2 Blockchain, accumulating $DOG for its treasury. The 'Dog Army' is actively pushing for broader exchange listings and celebrating its unique position within the Bitcoin ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Spirit of the Coast Analytics said Anavex’s Alzheimer’s drug Blarcamesine is likely to gain conditional marketing authorization (CMA) from the European Medicines Agency, citing strong long-term efficacy data despite limited trial size.</li><li>The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization.</li><li>On Stocktwits, traders praised the analysis as “best in class,” with some predicting off-label use across other dementia types and urging patience for long-term gains.</li></ul>Anavex Life Sciences shares drew some retail chatter on Tuesday after a new report from Spirit of the Coast Analytics projected that the company’s lead Alzheimer’s drug, Blarcamesine, could secure conditional approval in Europe and attract a major pharmaceutical partner to accelerate commercialization.<h2 class="st-heading-2">EMA Conditional Approval Expected</h2>Spirit of the Coast Analytics&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sotcanalytics.com/update-compendium-2025#h.j7yb7yv7gs20">said</a> it believes Blarcamesine is “likely (though not definitive)” to receive conditional marketing authorization (CMA) from the European Medicines Agency (EMA). The report said the EMA often prefers granting conditional approval rather than outright denial for drugs addressing major unmet medical needs, particularly when data show large effect sizes.Analysts noted that Blarcamesine’s existing Phase 2b/3 data, while limited in sample size and missing one co-primary endpoint, showed statistically strong results and sustained efficacy over 192 weeks in long-term studies. The report emphasized that any conditional approval would reflect “incomplete” data, not doubts over validity.<h2 class="st-heading-2">Market Potential And Pricing Forecasts</h2>The report projected that Blarcamesine could capture up to 40% market share among early-stage Alzheimer’s patients across the U.S. and Europe, translating into tens of billions in potential revenue at peak.Spirit of the Coast estimated that the drug’s price could range between $10,000 and $18,200 per year in the U.S. and $8,000 and $14,000 in Europe, based on quality-adjusted life year (QALY) analysis. The analysts said the drug’s oral delivery, strong safety profile, and lack of complex monitoring requirements would support broad adoption and payer acceptance.<h2 class="st-heading-2">Partnership Pathway Viewed As Essential</h2>The report said Anavex “almost certainly requires a big-pharma partnership” to achieve its commercial potential. Analysts projected a possible multi-billion-dollar upfront payment with tiered royalty milestones under such a deal, noting that large pharmaceutical companies would likely seek to collaborate given the drug’s market opportunity and safety data.The report also said a partnership could accelerate regulatory engagement and manufacturing scale-up, allowing Anavex to compete more effectively against higher-priced monoclonal antibody therapies such as Leqembi and Kisunla.<h2 class="st-heading-2">Stocktwits Traders See Upside But Cautious On Long-Term Gains</h2>On Stocktwits, retail sentiment for Avanex was ‘bearish’ amid ‘normal’ message volume.One user called the analysis “best in class,” saying it highlighted “super-massive potential” for Blarcamesine, including off-label use in other dementias, and urged investors to “strap in” for the long term rather than selling early.<stembedurl>https://stocktwits.com/Veliger/message/633171391</stembedurl>Another user said the projections seemed “mathematically sound” but warned of a “fantasyland vibe,” estimating a 90% chance of approval and noting that retail investors’ gains may hinge on whether Anavex opts for a partnership or a buyout.<stembedurl>https://stocktwits.com/ItsThrillhouse/message/633175141</stembedurl><a href="https://stocktwits.com/symbol/AVXL">Avanex’s stock</a> has declined 13% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avanex’s stock has declined 13% so far in 2025. (Photo credit: Getty Images)

Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up

The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization.

Equity

Anavex Life Sciences (AVXL) on Thursday said that its investigational drug achieved its primary endpoint in a mid-stage trial and demonstrated safety and tolerability in adults with Schizophrenia.Shares of the company soared 9% in Thursday’s pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160275/29248/en/Anavex-Life-Sciences-Announces-Positive-Topline-Results-from-Phase-2-Study-of-ANAVEX-3-71-for-the-Treatment-of-Schizophrenia.html">said</a> that the safety profile of ANAVEX3-71 was consistent with previous studies in healthy volunteers, and no serious treatment-emergent adverse events were reported in the study.The company is evaluating the drug in the treatment of Schizophrenia, a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide. According to Anavex, the illness impacts 2.8 million people in the U.S. alone.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘high’ levels.Anavex also said on Thursday that encouraging trends were observed in biomarkers of Schizophrenia in the study that support continued development. This includes a reduced glial fibrillary acidic protein in patients receiving ANAVEX3-71 compared to placebo.GFAP is a marker of neuroinflammation, and a reduction in it suggests a potential disease-modifying effect that may become more pronounced with longer treatment durations, the company said.The company on Thursday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160281/29248/en/Anavex-Life-Sciences-Announces-Successful-Development-of-Once-Daily-Oral-Tablet-Formulation-for-the-ANAVEX-3-71-Program.html">announced</a> the successful development of a once-daily oral tablet formulation for the ANAVEX3-71 program. The tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing, it added.AVXL stock is down 16% this year but up approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-slashes-full-year-delivery-guidance-after-drop-in-q3-figures/chCrfpbR3OH">Rivian Slashes Full-Year Delivery Guidance After Drop In Q3 Figures</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

The company said that its investigational drug for Schizophrenia achieved its primary endpoint in a mid-stage trial.

Anavex Life Sciences Corp. (AVXL) on Tuesday announced that its experimental Alzheimer’s drug demonstrated cognitive stabilization in patients with early Alzheimer’s disease in a study.After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine in a precision medicine population demonstrated barely detectable cognitive decline on all standard scales for measuring cognitive decline, comparable to the minimal decline in pre-dementia aging adults.Shares of the company rose 2% on Tuesday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-announces-oral-blarcamesine-cognitive-resilience-results-approximating-normal-a">said</a> that the drug caused about an 84.7% reduction in cognitive decline as compared to placebo on a standardized neuropsychological test used in Alzheimer's disease research to measure cognitive function.“Today’s new clinical efficacy data update from our Phase IIb/III trial is critical, as it adds contemporary context to Precision Medicine data showing strong protection from Alzheimer’s disease with an oral once-daily potential solution with the aim to alleviate significant medical and economic burden,” said Juan Carlos Lopez-Talavera, Head of Research and Development of Anavex.Anavex will continue to evaluate trial data, which will be published and presented at international conferences, the company said.Anavex is also studying Blarcamesine, its lead candidate, in dementia caused by Parkinson's disease, a neurodegenerative brain condition, and in patients with Rett syndrome, a rare genetic neurological and developmental disorder that affects the way the brain develops.AVXL stock is down 12% this year but up approximately 84% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-1.5-million-vehicles-in-us/chwKduPRdte">Ford Draws Retail Investor Concerns After It Recalls Nearly 1.5M Vehicles In US Over Rear View Camera Display Issues</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study

After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 

Anavex Life Sciences slipped in after-hours trading on Monday after the company said it plans to raise&nbsp;as much as $300 million by selling shares.The stock closed at $11.48 on Monday, up 3.3% for the day, before slipping 1% to $11.37 in after-hours trading.The stock offering comes on the heels of its latest quarterly results,&nbsp;which showed net loss was $11.2 million, or $0.13 a share, compared with a loss of $10.5 million in the same period last year.&nbsp;The company had $115.8 million in cash at the end of March and said that it would fund the company for about four years.In April, Anavex disclosed an update on the long-term data on its Alzheimer’s candidate, blarcamesine. According to new data released, the drug slowed cognitive decline in early-stage Alzheimer’s patients over&nbsp;four years.&nbsp;The results were disclosed at the AD/PD 2025 conference, and they hint that the treatment may have a disease-modifying effect if started early and taken continuously.The drug has also been well tolerated. No&nbsp;significant safety issues were reported, and dizziness, the most common side effect, was reduced by tweaking the dose schedule.Anavex has also wrapped up enrollment for a mid-stage trial of its schizophrenia drug, Anavex 3-71, with results expected in the second half of the year.&nbsp;Separately, 74 patients remain on long-term blarcamesine therapy through a Compassionate Use Program, with some having taken the drug daily for over nine years.On Stocktwits, retail sentiment for Anavex was ‘extremely bullish’ amid ‘high’ message volume.One user viewed the shelf registration as a bullish signal, suggesting that Anavex may be positioning itself for a potential EMA approval.&nbsp;They speculated the filing could be tied to plans for standalone distribution or as a strategic move to strengthen the company’s hand in partnership talks, calling it “nothing but good news” for long-term holders.<stembedurl>https://stocktwits.com/PartyNaked/message/620947957</stembedurl>Another user said that the S-3 filing doesn’t mean an immediate offering, but rather gives the company flexibility to raise funds if needed, particularly after a major catalyst like an EMA decision.&nbsp;They called the move smart and standard for biotech firms, arguing it allows Anavex to act quickly if the stock jumps post-approval and strengthens its negotiating position with potential partners.<stembedurl>https://stocktwits.com/kay91667/message/620942567</stembedurl>Anavex’s stock has declined 5.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avanex Life Sciences (AVXL) said it plans to raise up to $300 million by selling shares. (Photo credit: Getty Images)

Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It’s A ‘Smart’ Move 

The after-hours move followed Anavex’s recent completion of enrollment for a mid-stage schizophrenia trial, with top-line results expected later this year. 

Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging  Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday. The stocks trending the most on the Stocktwits platform include Webull, SharpLink, Anavex Life Sciences, BigBear.ai, and Oscar Health.1. Webull Corp. (BULL)<img src="https://news.stocktwits-cdn.com/BULL_png_3a86d4a0fc.webp" alt="BULL.png">2. SharpLink Gaming Ltd. (SBET)<img src="https://news.stocktwits-cdn.com/SBET_png_ddf51dbef1.webp" alt="SBET.png">3. Anavex Life Sciences Corp. (AVXL)<img src="https://news.stocktwits-cdn.com/AVXL_png_b962881047.webp" alt="AVXL.png">4. BigBear.ai Holdings Inc. (BBAI)<img src="https://news.stocktwits-cdn.com/BBAI_png_3156927dd7.webp" alt="BBAI.png">5. Oscar Health Inc. (OSCR)<img src="https://news.stocktwits-cdn.com/OSCR_png_e8f637dd66.webp" alt="OSCR.png">Disclaimer: Stocktwits' "Why It's Trending" summary is AI-generated and may contain errors.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-us-make-fortune-if-big-beautiful-bill-is-passed-but-house-republicans-could-sink-it/chF0ot3RTyE">Trump Says US Will ‘Make A Fortune’ If The Big Beautiful Bill Is Passed, But House Republicans Could Sink It</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 06, 2024 in New York City as the market opened after the worst crash since 2022

Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday.

Lightning Round: Sell Viking Therapeutics, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, Transocean, and DuPont...

Anavex Life Sciences Corp., a small-cap biotech specializing in neurodegenerative and neurodevelopmental diseases, emerged as the top pick among retail investors in a recent Stocktwits poll.&nbsp;Nearly 45% of respondents believe Anavex will outperform in the first quarter of 2025, compared to 33% for Novavax and 9% for Rigel Pharmaceuticals.<stembedurl>https://stocktwits.com/StocktwitsPolls/message/599783274</stembedurl>Alzheimer’s Therapy MomentumAnavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73), whose European Marketing Authorization Application was&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/avxl-stock-rises-on-q4-results-ema-nod-for-blarcamesine/cJazDmdRj5">accepted</a> last month.&nbsp;Promising trial results showed three years of continuous blarcamesine treatment significantly reduced clinical decline in early Alzheimer’s patients, with no safety issues reported.&nbsp;That positions the drug as a potential breakthrough, especially as interest in Alzheimer’s therapies intensifies following recent setbacks for rivals like Cassava Sciences.The company’s stock surged over 76% in 2024 but is down 6% year-to-date, with a high short interest of 24.5% as per Koyfin data.&nbsp;Anavex reported $132.2 million in cash reserves as of Sept. 30, 2024, and projects a four-year cash runway at its current burn rate.Vaccine Maker Eyes RecoveryNovavax has maintained momentum after a 68% gain in 2024, with shares up nearly 6% this year.&nbsp;The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvax-stock-is-undervalued-say-retail-investors/chGWtkSRZy">recovered</a> from an FDA clinical hold on its COVID-19 and flu combination vaccine late last year, thanks to a $50 million milestone payment under its Sanofi partnership and increasing hopes for a bird flu vaccine.&nbsp;Novavax holds the largest market cap among the three at $1.38 billion. It has $909.5 million in cash and a manageable debt load of $262 million, which many retail investors see as an advantage.&nbsp;It also has a high short interest of 24.5%.Under-The-Radar Bet?Rigel Pharmaceuticals focuses on autoimmune and hematologic diseases. The company recently received orphan drug designation for R289, a treatment for lower-risk myelodysplastic syndromes.&nbsp;A growing portfolio of approved therapies, such as TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for acute myeloid leukemia has also boosted retail sentiment.On Monday, the company said it expects fourth-quarter revenue of $57.6 million, up 61% year-over-year and above a Wall Street estimate of $47.4 million. It also projected 2025 revenue of $200-$210 million, better than an expected $193.5 million.Rigel’s stock rose 15% in 2024 and remained nearly flat in 2025. As of Dec. 31, 2024, it had estimated cash reserves of $77.3 million.&nbsp;Rigel’s short interest is relatively low at 3.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Anavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73). | Image source: Getty Images 

Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

Anavex Life Sciences Corp. shares rocketed over 27% on Monday, hitting their highest levels since February 2023, fueled by a mix of positive earnings results and regulatory progress in Europe.The biopharma company, focused on neurodegenerative and neurodevelopmental diseases, reported a fiscal fourth-quarter loss of $11.6 million, or an adjusted $0.14 per share, compared to a loss of $10.1 million in the year-ago period.&nbsp;While research and development (R&amp;D) and overhead costs rose, the per-share loss was narrower than the FactSet consensus estimate of $0.16.Anavex also highlighted a strong cash position, with $132.2 million in reserves, which the company says will provide a four-year runway at current burn rates.Creating more buzz was news that the European Medicines Agency (EMA) accepted the Marketing Authorization Application for blarcamesine (ANAVEX 2-73), an investigational oral drug for Alzheimer’s disease.&nbsp;Anavex’s Head of R&amp;D, Juan Carlos Lopez-Talavera, said: "The EMA filing acceptance for blarcamesine to review the Marketing Authorization Application potentially brings us a step closer offering broader patient access to a new treatment option in Europe, and we look forward to continued engagement with the EMA.”CEO Christoper Missling said, "We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains deeply committed to executing on our momentum.”<figure class="image"><img style="aspect-ratio:1326/1056;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_poll_sentiment_and_message_volume_Dec_24_fe40cd4f12.png" alt="AVXL poll sentiment and message volume Dec 24.png" width="1326" height="1056"><figcaption>AVXL poll, sentiment and message volume on Dec 24 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits celebrated the news, with sentiment shifting sharply to ‘bullish’ from ‘neutral.’&nbsp;Many hailed the EMA filing as a significant milestone, with one user claiming very high approval rates by the European regulator for “accepted drug candidates in 2024 that aren't withdrawn.”<stembedurl>https://stocktwits.com/Guzzi62/message/597573043</stembedurl><stembedurl>https://stocktwits.com/PhillipHerass/message/597572113</stembedurl><stembedurl>https://stocktwits.com/Logic102/message/597572650</stembedurl>According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10499418/">study</a> published last year in the Clinical and Translational Science, an official journal of the American Society for Clinical Pharmacology and Therapeutics, the EMA was found to have the highest approval rate (93.8%) for non-oncology products when compared with Swiss and U.S. regulators. The data analyzed decisions between 2009 and 2018 on new active substances.The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh">reported</a> disappointing results for its candidate simufilam last month.&nbsp;D. Boral Capital had noted Anavex’s neuroprotective mechanism could position blarcamesine as a superior option, reiterating a ‘Buy’ rating with a $46 price target.Anavex shares are now up 88% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

EMA European Medicines Agency at Canary Wharf on 5th November 2024 in London, United Kingdom. (photo by Mike Kemp/In Pictures via Getty Images)

Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer’s Drug: Retail’s Overjoyed

The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences reported disappointing results for its candidate simufilam last month.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.14	--	--	N/A
Q3 '25	-$0.14	-$0.16	-12.41%	MISSED
Q2 '25	-$0.15	-$0.13	13.33%	BEAT
Q1 '25	-$0.17	-$0.14	17.65%	BEAT
Q4 '24	-$0.16	-$0.14	14.29%	BEAT

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AVXL News

AVXLAnavex Life Sciences Corp